title: Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.
abstract: Drug-induced liver injury is a prominent reason for premarketing and postmarketing drug withdrawal and can be manifested in a number of ways, such as cholestasis, steatosis, and fibrosis. The mechanisms driving these toxicological processes have been well characterized and have been emdedded in adverse outcome pathway frameworks in recent years. This review evaluates these constructs and simultaneously illustrates their use in the preclinical testing of drug-induced liver injury.
authors.affiliation: Department of In Vitro Toxicology and Dermato-Cosmetology, Vrije Universiteit Brussel, Brussels, Belgium.
authors.forename: Mathieu
authors.initials: M
authors.lastname: Vinken
mesh_terms: D000077300:Bosentan; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism / Q000473:pathology*; D002779:Cholestasis / Q000139:chemically induced / Q000473:pathology; D005234:Fatty Liver / Q000139:chemically induced / Q000473:pathology; D006801:Humans; D008103:Liver Cirrhosis / Q000139:chemically induced / Q000473:pathology; D008727:Methotrexate / Q000633:toxicity; D021281:Quantitative Structure-Activity Relationship; D013449:Sulfonamides / Q000633:toxicity; D014635:Valproic Acid / Q000633:toxicity
chemical_list: D013449:Sulfonamides; D014635:Valproic Acid; D000077300:Bosentan; D008727:Methotrexate